Viral Decay Dynamics in HIV-Infected Patients Receiving Ritonavir-Boosted Saquinavir and Efavirenz With or Without Enfuvirtide: A Randomized, Controlled Trial (HIV-NAT 012)

Boyd, Mark A.; Dixit, Narendra M.; Siangphoe, Umaporn; Buss, Neil E.; Salgo, Miklos P.; Lange, Joep M. A.; Phanuphak, Praphan; Cooper, David A.; Perelson, Alan S.; Ruxrungtham, Kiat
November 2006
Journal of Infectious Diseases;11/1/2006, Vol. 194 Issue 9, p1319
Academic Journal
The availability of enfuvirtide enables assessment of whether human immunodeficiency virus (HIV) decay can be enhanced by targeting reverse transcriptase, protease, and fusion. We performed a 12-week study of 22 patients randomized to receive ritonavir-boosted saquinavir and efavirenz with (the 3-target arm) or without (the 2-target arm) enfuvirtide. We observed served no difference in the mean ± SD elimination-rate constant for overall decay (0.142 ± 0.040 per day and 0.128 ± 0.033 per day in the 2- and 3-target arms, respectively; P> .1) or for modeled first-phase decay rate (-0.62 ± 0.34 per day and -0.51 ± 0.16 per day; P> .1). Antiretroviral therapy that inhibits HIV reverse transcriptase and protease exerts potent antiviral effects that might not be augmented by the addition of an HIV fusion inhibitor.


Related Articles

  • A Cluster Randomized Trial of Routine HIV-1 Viral Load Monitoring in Zambia: Study Design, Implementation, and Baseline Cohort Characteristics. Koethe, John R.; Westfall, Andrew O.; Luhanga, Dora K.; Clark, Gina M.; Goldman, Jason D.; Mulenga, Priscilla L.; Cantrell, Ronald A.; Chi, Benjamin H.; Zulu, Isaac; Saag, Michael S.; Stringer, Jeffrey S. A. // PLoS Clinical Trials;Mar2010, Vol. 7 Issue 3, Special section p1 

    Background:The benefit of routine HIV-1 viral load (VL) monitoring of patients on antiretroviral therapy (ART) in resource-constrained settings is uncertain because of the high costs associated with the test and the limited treatment options. We designed a cluster randomized controlled trial to...

  • Treatment of HIV/AIDS: Do the Dilemmas Only Increase? Sande, Merle A.; Ronald, Allan // JAMA: Journal of the American Medical Association;7/14/2004, Vol. 292 Issue 2, p266 

    Presents an editorial on HIV/AIDS treatment and mentions articles in this issue of "JAMA". Guidelines set by the International AIDS Society-USA (IAS-USA) for HIV care reported in this issue; View that clinical trials using highly active antiretroviral therapy (HAART) should be redirected to...

  • Response to Combined Antiretroviral Therapy According to Gender and Origin in a Cohort of Naïve HIV-Infected Patients: GESIDA-5808 Study. Pérez-Molina, José A.; Mora Rillo, Marta; Suárez-Lozano, Ignacio; Casado-Osorio, Jose L.; Teira Cobo, Ramón; Rivas González, Pablo; Pedrol Clotet, Enric; Hernando-Jerez, Asunción; Domingo, Pere; Barquilla Díaz, Elena; Esteban, Herminia; González-García, Juan; for the GESIDA 5808 Study Group* // HIV Clinical Trials;May/Jun2012, Vol. 13 Issue 3, p131 

    Background: We analyzed differences in response to combined antiretroviral therapy (cART) according to sex and geographic origin in a retrospective comparative study of Spanish-born and immigrant patients initiating cART. Methods: The primary endpoint was time to treatment failure (TTF), defined...

  • Seroconversion Following Nonoccupational Postexposure Prophylaxis against HIV. Roland, Michelle E.; Neilands, Torsten B.; Krone, Melissa R.; Katz, Mitchell H.; Franses, Karena; Grant, Robert M.; Busch, Michael P.; Hecht, Frederick M.; Shacklett, Barbara L.; Kahn, James O.; Bamberger, Joshua D.; Coates, Thomas J.; Chesney, Margaret A.; Martin, Jeffrey N. // Clinical Infectious Diseases;11/15/2005, Vol. 41 Issue 10, p1507 

    Background. The efficacy of antiretroviral postexposure prophylaxis (PEP) against infection with human immunodeficiency virus (HIV) following occupational exposures has prompted the use of PEP after nonoccupational exposures. There are, however, important differences between occupational and...

  • HIV Antiretroviral Postexposure Prophylaxis: A Cautionary Note. Cohen, Myron S.; Kashuba, Angela D. M.; Gay, Cynthia // Clinical Infectious Diseases;11/15/2005, Vol. 41 Issue 10, p1514 

    Presents the authors' opinions on the role of antiretroviral therapy in preventing the sexual transmission of human immunodeficiency virus (HIV) infection. Discussion on clinical trials to evaluate the efficacy of antiretroviral therapy; Views on the benefits of pre-exposure prophylaxis;...

  • Global: clinical trial shows dramatic reduction in transmission of HIV as a result of treatment. Cozac, David // HIV/AIDS Policy & Law Review;Oct2011, Vol. 15 Issue 3, p31 

    The article reports on a clinical trial conducted by the U.S. HIV Prevention Trials Network which revealed that human immunopdeficiency virus (HIV)-positive persons' adherence to an effective antiretroviral therapy reduce the risk of virus transmission by 96 percent. The trial confirmed that HIV...

  • HIV Infection-Associated Tuberculosis: The Epidemiology and the Response. Getahun, Haileyesus; Gunneberg, Christian; Granich, Reuben; Nunn, Paul // Clinical Infectious Diseases;May2010 Supplement 3, Vol. 50, pS201 

    Of the 33.2 million persons infected with human immunodeficiency virus (HIV), one-third are estimated to also be infected with Mycobacterium tuberculosis. In 2008, there were an estimated 1.4 million new cases of tuberculosis (TB) among persons with HIV infection, and TB accounted for 26% of...

  • Physician Estimate of Antiretroviral Adherence in India: Poor Correlation with Patient Self-Report and Viral Load. Walshe, L.; Saple, D. G.; Mehta, S. H.; Shah, B.; Bollinger, R. C.; Gupta, A. // AIDS Patient Care & STDs;Mar2010, Vol. 24 Issue 3, p189 

    Adherence to antiretroviral therapy (ART) is critical in maintaining viral suppression and minimizing resistance in HIV-infected patients. We compared physician estimates of their patients' ART adherence with participant's self-reported adherence to determine patient-provider agreement and...

  • Probiotics Reduce Inflammation in Antiretroviral Treated, HIV-Infected Individuals: Results of the “Probio-HIV” Clinical Trial. d’Ettorre, Gabriella; Ceccarelli, Giancarlo; Giustini, Noemi; Serafino, Sara; Calantone, Nina; De Girolamo, Gabriella; Bianchi, Luigi; Bellelli, Valeria; Ascoli-Bartoli, Tommaso; Marcellini, Sonia; Turriziani, Ombretta; Brenchley, Jason M.; Vullo, Vincenzo // PLoS ONE;9/16/2015, Vol. 10 Issue 9, p1 

    Background: HIV infection results in damage to the gastrointestinal (GI) tract, microbial translocation and immune activation. These are not completely normalized with combined antiretroviral therapy (cART). Moreover, increate morbidity and mortality of cART-treated HIV-infected individuals is...

  • Long-Term Effects of Intermittent IL-2 in HIV Infection: Extended Follow-Up of the INSIGHT STALWART Study. Markowitz, Norman; Lopardo, Gustavo; Wentworth, Deborah; Gey, Daniela; Babiker, Abdel; Fox, Lawrence; Tavel, Jorge // PLoS ONE;Oct2012, Vol. 7 Issue 10, Special section p1 

    Background: The Study of Aldesleukin with and without Antiretroviral Therapy (STALWART) was designed to evaluate whether intermittent IL-2 alone or with peri-cycle ART increased CD4+ cell counts (and so delayed initiation of ART) in HIV infected individuals having ≥300 CD4+ cells/mm³...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics